An extensive analysis shows scant evidence that ketamine or other NMDA receptor agonists reduce chronic noncancer pain but ...

By Lori Solomon HealthDay ReporterMONDAY, Aug. 18, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

The U.S. Food and Drug Administration has approved the ketamine product, KETARx, for use in surgical pain management.

A sweeping review of 67 trials has cast doubt on the use of ketamine and similar NMDA receptor antagonists for chronic pain relief. While ketamine is frequently prescribed off-label for conditions ...

The off-label use of ketamine to treat chronic pain is not supported by scientific evidence, a new Cochrane review has found.

Researchers cautioned that the existing evidence base is too poor to draw any solid conclusions on whether ketamine can help ...

A Cochrane review assessed ketamine and other NMDA receptor antagonists for chronic non-cancer pain. The evidence was low to very low certainty, showing no clear pain relief and potential adverse ...

A major Cochrane review found no convincing evidence that ketamine or similar NMDA-blocking drugs improve chronic non-cancer ...

Ketamine is regularly used for the treatment of chronic pain, but a new report shows there is no clear evidence of its benefit.The off-label use of ...

A strong anesthetic ‘Ketamine’ is normally used in hospital procedures. Ketamine is also used for short-term pain management in hospitals. It works by blocking a brain signal ...